Randy Teel Sells 4,403 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 4,403 shares of Arvinas stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $52,351.67. Following the completion of the transaction, the chief executive officer directly owned 154,482 shares in the company, valued at approximately $1,836,790.98. This represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Arvinas Stock Up 5.2%

ARVN stock opened at $12.44 on Friday. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $19.15. The company has a market cap of $798.90 million, a PE ratio of -15.36 and a beta of 1.88. The business’s 50-day simple moving average is $12.38 and its 200 day simple moving average is $10.35.

Institutional Investors Weigh In On Arvinas

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC lifted its stake in shares of Arvinas by 50.0% during the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after acquiring an additional 600,000 shares during the period. TCG Crossover Management LLC bought a new position in shares of Arvinas in the 3rd quarter valued at about $13,780,000. Geode Capital Management LLC grew its position in shares of Arvinas by 3.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock worth $11,668,000 after buying an additional 48,296 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Arvinas by 154.8% during the third quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after buying an additional 903,337 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Arvinas by 791.1% in the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after buying an additional 1,267,593 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARVN has been the topic of a number of recent research reports. BTIG Research lifted their price objective on Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wedbush reaffirmed a “neutral” rating and issued a $9.00 target price on shares of Arvinas in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Barclays raised their price objective on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $10.00 to $15.00 in a report on Tuesday, January 6th. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Arvinas has a consensus rating of “Hold” and a consensus price target of $13.12.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.